- Merz bids above Valeant for Obagi's skin products
- Valeant fronts $344m for skin product firm Obagi
- DEALS ROUND-UP: M&A and partnering 1-28 December
- US Capitol Capsule: Meningitis outbreak spotlights fuzzy pharmacy compounding oversight
ONLY 0 DAY LEFT
|Stay close to your market. Renew online now to ensure uninterrupted access to:|
|SCRIP Intelligence's news and expert commentary|
|Market Data and Company Analysis (SCRIP 100, SCRIP Asia 100)|
|The Ask the Analyst Service...and more.|
Please remember to quote your order number and customer number.
You can also renew by calling: +44 (0)20 7017 5540.